All Articles by Author:

Justin.choi

Diosgenin Derivatives Developed from Pd(ii) Catalysed Dehydrogenative Coupling Exert an Effect on Breast Cancer Cells by Abrogating Their Growth and Facilitating Apoptosis via Regulating...

[Dalton Transactions] Based on the pharmacological importance of diosgenin, the obtained derivatives were exposed to study their effect on breast cancer cells where they significantly reduced the growth of cancer cells and left non-malignant breast epithelial cells unaffected.

Clinically Relevant CHK1 Inhibitors Abrogate Wild-Type and Y537S Mutant ERα Expression and Proliferation in Luminal Primary and Metastatic Breast Cancer Cells

[Journal of Experimental & Clinical Cancer Research] The authors evaluated if kinases could be new targets for the treatment of luminal primary and metastatic breast cancers.

Nrf2 and NF-κB/NLRP3 Inflammasome Pathways Are Involved in Prototheca bovis Infections of Mouse Mammary Gland Tissue and Mammary Epithelial Cells

[Free Radical Biology and Medicine] Investigators characterized how Prototheca bovis induced inflammatory responses in mouse mammary gland tissue and mammary epithelial cells.

Modified Bovine Milk Exosomes for Doxorubicin Delivery to Triple-Negative Breast Cancer Cells

[ACS Applied Bio Materials] Scientists described the use of two chemical modifications, incorporating a neuropilin receptor agonist peptide and a hypoxia-responsive lipid for targeting and release of an encapsulated drug from bovine milk exosomes toTNBC cells.

Dinaciclib Inhibits the Stemness of Two Subtypes of Human Breast Cancer Cells by Targeting the FoxM1 and Hedgehog Signaling Pathway

[Oncology Reports] Investigators aimed to examine the stemness‑inhibitory effects of dinaciclib in MCF‑7 and HCC‑1806 breast cancer cells.

Breast Cancer in the Era of Integrating “Omics” Approaches

[Oncogenesis] The authors investigated the correlation between different “omics” datasets and to define the new important key pathway and upstream regulators in breast cancer.

Popular

Challenges and Opportunities in Combining Radiotherapy and Immunotherapy for Localized Pancreatic Cancer

[Nature Reviews Gastroenterology & Hepatology] Expanding preclinical and clinical literature from PDAC and other oncological indications identifies novel approaches through which radiation therapy–immunotherapy combinations could improve local and systemic disease control in patients with PDAC.

Developmental and MAPK-Responsive Transcription Factors Regulate Distinct Malignant Cell States and Associated Genetic Dependencies in Pancreatic Cancer

[Nature Genetics] Single-cell master regulator analysis of multiple pancreatic ductal adenocarcinoma cohorts identified malignant cells in three co-existing, molecularly distinct developmental lineage states, with distinct histopathological morphologies and spatial architecture.

FDA Approves First in Class Targeted Therapy for Metastatic Pancreatic Cancer

[US FDA] The US FDA approved Rasonque (daraxonrasib), a RAS inhibitor for the most common form of pancreatic cancer—delivering a new treatment option to patients with advanced pancreatic cancer months ahead of schedule.